2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07C.13 Aumolertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage I NSCLC with Multiple High-Risk Factors

EP.07C.13 Aumolertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage I NSCLC with Multiple High-Risk Factors

Pdf Summary

The study examines the use of aumolertinib, a third-generation EGFR-TKI, as an adjuvant therapy in patients with stage I EGFR-mutated non-small cell lung cancer (NSCLC) who are considered high-risk due to various factors. Typically, surgery is the primary treatment for early-stage NSCLC; however, about 20% of stage I patients experience early recurrence or metastasis even after surgery. High-risk factors contributing to poor prognosis include imaging, pathology, surgical methods, gene mutations, and MRD ctDNA positivity. <br /><br />In this study, 26 patients with stage I EGFR-mutated lung adenocarcinoma who had previously undergone resection were enrolled from April 2021 to January 2024. Among these patients, 17 (65%) presented high-risk factors, and 13 (50%) had two combined high-risk factors. Key risk factors identified were the presence of solid, micropapillary, or complex gland components, poorly differentiated carcinoma, pleural invasion, non-EGFR co-mutations, surgical approach, and smoking history.<br /><br />Following surgery, all patients received daily oral doses of aumolertinib (110 mg) until recurrence, treatment completion, or meeting criteria for discontinuation. At the data cut-off, none of the patients showed symptoms of tumor recurrence, and 13 individuals had been followed for over a year, all remaining alive and disease-free, with a one-year disease-free survival (DFS) rate of 100%. Side effects were minimal, with only one patient experiencing a mild rash.<br /><br />The study concludes that aumolertinib shows efficacy and has a safety profile that is tolerable in stage I EGFR-mutated NSCLC patients post-surgery with multiple high-risk factors. Further analysis is underway to assess long-term outcomes of the treatment.

Asset Subtitle

Qifei Wu

Meta Tag

Speaker Qifei Wu

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

aumolertinib

EGFR-TKI

adjuvant therapy

stage I NSCLC

high-risk factors

lung adenocarcinoma

disease-free survival

post-surgery treatment

EGFR mutations

safety profile